Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study.
暂无分享,去创建一个
Manuela A Joore | Sabine E Grimm | Bram L T Ramaekers | Svenja Petersohn | Arina J Ten Cate-Hoek | M. Joore | B. Ramaekers | A. T. ten Cate‐Hoek | S. Grimm | S. Petersohn | Sabine E. Grimm
[1] David Moher,et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[2] D. Spiegelhalter,et al. Disease Mapping With WinBUGS and MLwiN, Bayesian Approaches to Clinical Trials and Health Care Evaluation , 2004 .
[3] Khalid Yusoff,et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2017, Lancet.
[4] Ken Stein,et al. Informing Reimbursement Decisions Using Cost-Effectiveness Modelling: A Guide to the Process of Generating Elicited Priors to Capture Model Uncertainties , 2017, PharmacoEconomics.
[5] K. Payne,et al. Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations , 2016, PharmacoEconomics.
[6] Philippe Beutels,et al. Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic Models , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.
[7] Ken Stein,et al. EXPLICIT: a feasibility study of remote expert elicitation in health technology assessment , 2017, BMC Medical Informatics and Decision Making.
[8] Mark Strong,et al. Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[9] David Schultz,et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.
[10] W. Walker,et al. Defining Uncertainty: A Conceptual Basis for Uncertainty Management in Model-Based Decision Support , 2003 .
[11] M. Joore,et al. Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments , 2019, Quality of Life Research.
[12] H. V. van Stel,et al. Impact of secondary cardiovascular events on health status. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[13] Karl Claxton,et al. Exploring Uncertainty in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.
[14] Elisabeth Fenwick,et al. Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[15] Karl Claxton,et al. Eliciting distributions to populate decision analytic models. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[16] M. Hunink,et al. Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: a randomized controlled trial. , 2008, Journal of vascular surgery.
[17] Salah Ghabri,et al. Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines , 2018, PharmacoEconomics.
[18] M. Prins,et al. Cost-effectiveness of exercise therapy in patients with intermittent claudication: supervised exercise therapy versus a 'go home and walk' advice. , 2011, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[19] M. Sculpher,et al. Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts , 2020, Medical decision making : an international journal of the Society for Medical Decision Making.
[20] Erik Lebret,et al. The use of expert elicitation in environmental health impact assessment: a seven step procedure , 2010, Environmental health : a global access science source.
[21] Andrew Briggs,et al. An Introduction to Markov Modelling for Economic Evaluation , 1998, PharmacoEconomics.
[22] John Paul Gosling,et al. SHELF: The Sheffield Elicitation Framework , 2018 .
[23] Mark Strong,et al. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment , 2017, PharmacoEconomics.
[24] Jeremy E. Oakley,et al. Probability is perfect, but we can't elicit it perfectly , 2004, Reliab. Eng. Syst. Saf..
[25] William Hollingworth,et al. Model Transparency and Validation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[26] A. Algra,et al. Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. , 2001, Journal of vascular surgery.
[27] M. Joore,et al. Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study , 2020, European journal of preventive cardiology.
[28] Christopher James Sampson,et al. Model Registration: A Call to Action , 2017, PharmacoEconomics - Open.
[29] D. Clement. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .
[30] Jonathan Karnon,et al. Model Parameter Estimation and Uncertainty Analysis , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[31] Sean Ekins,et al. Time for Cooperation in Health Economics among the Modelling Community , 2012, PharmacoEconomics.
[32] F. Hamers,et al. Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers’ Submissions to the French National Authority for Health , 2016, PharmacoEconomics.
[33] Jeremy E. Oakley,et al. Managing structural uncertainty in health economic decision models: a discrepancy approach , 2012 .
[34] Andrew R Willan,et al. Optimal clinical trial design using value of information methods with imperfect implementation. , 2009, Health economics.
[35] Jeremy E. Oakley,et al. Estimating Multiparameter Partial Expected Value of Perfect Information from a Probabilistic Sensitivity Analysis Sample , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[36] J. Bosch,et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2018, Lancet.
[37] Kerrie Mengersen,et al. Characterising Uncertainty in Expert Assessments: Encoding Heavily Skewed Judgements , 2015, PloS one.
[38] Karl Claxton,et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[39] Saskia Knies,et al. Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models , 2019, PharmacoEconomics.
[40] Manuela A. Joore,et al. Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy , 2014, PharmacoEconomics.
[41] A. Algra,et al. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis , 2011, BMJ : British Medical Journal.
[42] M. Sculpher,et al. Catalogue of EQ-5D Scores for the United Kingdom , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.
[43] Karl Claxton,et al. Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[44] M L Simoons,et al. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? , 2001, European heart journal.